Key Takeaways
- GLP-1 is a naturally occurring gut hormone (glucagon-like peptide-1). Ozempic is one specific medication that mimics GLP-1.
- "GLP-1 receptor agonist" is the drug class. Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Trulicity, and Victoza are all members of this class.
- Ozempic's active ingredient is semaglutide. Wegovy is also semaglutide, just at a different dose and approved indication.
- Mounjaro and Zepbound are tirzepatide, a dual GLP-1 and GIP agonist. Tirzepatide produces larger average weight loss than semaglutide in head-to-head data (Frias et al., NEJM 2021).
- All GLP-1 receptor agonists work through similar mechanisms: appetite suppression, slowed gastric emptying, and improved insulin response.
- Saying "I'm on GLP-1" without naming the specific drug is imprecise, since dose, indication, and side-effect profile differ across the class.
Direct answer (40-60 words)
No, GLP-1 is not the same as Ozempic. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone, and "GLP-1 receptor agonist" is a drug class that includes many medications. Ozempic is one specific brand of semaglutide within that class. Other GLP-1 drugs include Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Victoza, and Saxenda.
Table of contents
- The 30-second answer
- What GLP-1 actually is
- What "GLP-1 receptor agonist" means
- The full list of GLP-1 medications
- Ozempic versus other GLP-1 drugs at a glance
- Are all GLP-1 medications interchangeable?
- Tirzepatide is technically a dual agonist, not a pure GLP-1
- The compounded semaglutide question
- Why patients often confuse the terms
- FAQ
- Sources
- Footer disclaimers
What GLP-1 actually is
GLP-1, glucagon-like peptide-1, is a peptide hormone produced by L-cells in the small intestine in response to food (Drucker, Cell Metab 2018). It belongs to a family of "incretin" hormones that the gut releases when nutrients arrive.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Native GLP-1 does several things:
- Stimulates insulin release from the pancreas in a glucose-dependent way.
- Suppresses glucagon release, which prevents the liver from dumping more glucose.
- Slows gastric emptying, which keeps food in the stomach longer.
- Acts on the hypothalamus to reduce appetite and food reward.
- Probably contributes to satiety signaling through vagal and central pathways.
The catch is that natural GLP-1 has a half-life of about 2 minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) breaks it down almost as fast as the gut releases it. That very short half-life is why injecting natural GLP-1 is not therapeutically useful.
The drugs in the GLP-1 receptor agonist class were engineered to bind the same receptor while resisting DPP-4 cleavage. That extends the half-life from minutes to hours or days, which makes daily or weekly dosing possible.
What "GLP-1 receptor agonist" means
A receptor agonist is a molecule that binds a receptor and activates it. A GLP-1 receptor agonist binds the GLP-1 receptor and triggers the same downstream signaling as native GLP-1, only longer.
The GLP-1 receptor agonist class is itself divided by:
- Half-life. Short-acting agonists (Byetta, Saxenda) need daily injection. Long-acting ones (Ozempic, Wegovy, Trulicity, Mounjaro, Zepbound) are once weekly.
- Approved indication. Some are approved for type 2 diabetes only. Others for chronic weight management. A few for both.
- Receptor selectivity. Most are selective for the GLP-1 receptor. Tirzepatide is a dual GLP-1 and GIP receptor agonist (Coskun et al., Mol Metab 2018), so it activates a second incretin pathway as well.
- Active ingredient. Semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, and tirzepatide are different molecules with different binding kinetics.
When someone says "I'm on a GLP-1," they could mean any of nine or ten different prescription products, with different doses, different indications, and different side-effect intensities.
The full list of GLP-1 medications
| Drug class member | Active ingredient | Brand names | Approved indications | Dosing |
|---|---|---|---|---|
| Semaglutide (injectable, T2D) | Semaglutide | Ozempic | Type 2 diabetes, cardiovascular risk reduction | Once weekly subcutaneous |
| Semaglutide (injectable, obesity) | Semaglutide | Wegovy | Chronic weight management, cardiovascular risk reduction | Once weekly subcutaneous |
| Semaglutide (oral) | Semaglutide | Rybelsus | Type 2 diabetes | Daily oral |
| Tirzepatide (T2D) | Tirzepatide | Mounjaro | Type 2 diabetes | Once weekly subcutaneous |
| Tirzepatide (obesity) | Tirzepatide | Zepbound | Chronic weight management, obstructive sleep apnea | Once weekly subcutaneous |
| Dulaglutide | Dulaglutide | Trulicity | Type 2 diabetes | Once weekly subcutaneous |
| Liraglutide (T2D) | Liraglutide | Victoza | Type 2 diabetes | Daily subcutaneous |
| Liraglutide (obesity) | Liraglutide | Saxenda | Chronic weight management | Daily subcutaneous |
| Exenatide (short-acting) | Exenatide | Byetta | Type 2 diabetes | Twice daily subcutaneous |
| Exenatide (extended) | Exenatide ER | Bydureon | Type 2 diabetes | Once weekly subcutaneous |
| Lixisenatide | Lixisenatide | Adlyxin (discontinued in U.S. 2023) | Type 2 diabetes | Daily subcutaneous |
Several entries above share an active ingredient. Ozempic and Wegovy are both semaglutide, the difference being approved indication and maximum dose. Mounjaro and Zepbound are both tirzepatide. Victoza and Saxenda are both liraglutide.
Ozempic versus other GLP-1 drugs at a glance
| Comparison | Ozempic | Other GLP-1 drugs |
|---|---|---|
| Active ingredient | Semaglutide | Varies by drug |
| Approved use | Type 2 diabetes, CV risk reduction | Diabetes, obesity, OSA, depending on drug |
| Average weight loss in trials | ~6% in SUSTAIN trials | Wegovy ~15%, Zepbound ~21%, Trulicity ~3% |
| Dosing | 0.25 mg to 2 mg once weekly | 0.25 mg to 2.4 mg (semaglutide), 2.5 to 15 mg (tirzepatide), etc. |
| FDA approved for weight loss | No | Wegovy, Zepbound, and Saxenda are approved for chronic weight management |
| Side-effect profile | Nausea, vomiting, diarrhea, constipation | Similar across class, severity varies with drug and dose |
Ozempic is approved for type 2 diabetes and cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease. It is not approved for weight loss alone, even though weight loss occurs as a common effect.
Wegovy is the same active ingredient at a higher maximum dose (2.4 mg weekly versus 2 mg) and with the chronic weight management indication.
Are all GLP-1 medications interchangeable?
No. Although the class shares a mechanism, individual drugs differ enough that they are not freely interchangeable.
Differences in efficacy.
- Tirzepatide produces larger average weight loss than semaglutide. SURPASS-2 showed tirzepatide 15 mg outperformed semaglutide 1 mg for HbA1c reduction in type 2 diabetes (Frias et al., NEJM 2021). SURMOUNT-1 versus STEP 1 cross-trial comparison shows ~21% versus ~15% mean weight loss.
- Liraglutide produces less weight loss than semaglutide at maximum approved doses.
- Dulaglutide produces less weight loss than semaglutide at typical doses.
Differences in dosing schedule.
- Once-weekly injectables (Ozempic, Wegovy, Trulicity, Mounjaro, Zepbound, Bydureon) are easier for adherence.
- Daily injectables (Victoza, Saxenda, Byetta) are more dose-tunable but require more frequent administration.
- Oral semaglutide (Rybelsus) has lower bioavailability and requires daily fasting administration.
Differences in side-effect profile.
- Tirzepatide has slightly higher nausea rates than semaglutide at peak dose, but lower rates of severe events in some trial comparisons.
- Liraglutide's daily dosing produces more steady-state nausea complaints than weekly semaglutide.
Differences in cost and coverage.
- Insurance coverage and copay amounts differ widely across the class.
- Ozempic and Mounjaro are approved for diabetes, which makes them more frequently covered.
- Wegovy and Zepbound are approved for weight management, which is more commonly excluded.
A patient switching from one GLP-1 to another typically restarts the titration schedule for the new drug, since cross-tolerance is partial.
Tirzepatide is technically a dual agonist, not a pure GLP-1
Tirzepatide (the active ingredient in Mounjaro and Zepbound) binds both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide receptor). GIP is a second incretin hormone produced by K-cells in the upper small intestine.
Activating both receptors at once produces:
- Larger insulin response than pure GLP-1 agonism in some patients.
- Potentially greater weight loss than pure GLP-1 agonism, supported by the SURMOUNT trial program.
- A slightly different side-effect profile, with relatively similar GI rates but distinct effects on lipid metabolism.
For everyday conversation, people often lump tirzepatide in with "GLP-1 medications" because the GLP-1 component is dominant in the public framing. Technically, calling tirzepatide a "GLP-1/GIP dual agonist" is more accurate (Coskun et al., Mol Metab 2018).
This distinction is occasionally relevant when comparing trial data or discussing why one drug worked when another did not.
The compounded semaglutide question
Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is the same active ingredient as Ozempic and Wegovy, but it is not the same product.
Differences:
- Compounded semaglutide is not FDA-approved.
- It is drawn from a multi-dose vial with a U-100 insulin syringe, not delivered through a pre-filled pen.
- It is not interchangeable with brand-name Ozempic or Wegovy.
- Pricing through licensed telehealth platforms typically runs $179 to $499 per month, often less than insurance copays for brand-name semaglutide.
Why patients consider it:
- Insurance does not cover Ozempic or Wegovy for their situation.
- Cash price for brand-name semaglutide is unaffordable.
- They want predictable monthly pricing without insurance paperwork.
What it is not:
- It is not "generic Ozempic." There is no FDA-approved generic semaglutide as of 2026.
- It is not free of regulatory difference. Compounded products have not gone through the FDA's review process.
- It is not appropriate for every patient. A licensed clinician should evaluate fit.
The decision about compounded versus brand-name semaglutide is a clinical and financial one. It is not a synonym question.
Why patients often confuse the terms
Several reasons drive the "is GLP-1 the same as Ozempic" confusion:
- Ozempic was first. The first GLP-1 to enter mainstream conversation, especially after the 2022 to 2023 social-media wave around weight loss. For many patients, "Ozempic" became a generic shorthand for the whole drug class.
- The names are unfamiliar. "Glucagon-like peptide-1 receptor agonist" is a mouthful. Most patients drop the technical name and use the brand they recognize.
- The marketing. Ozempic's distinctive "Oh-Oh-Oh" jingle ran for years on cable TV, attaching the brand name to the concept of weight loss in many viewers' minds.
- The press coverage. Major news outlets often used "Ozempic" as the headline word even when the underlying story was about GLP-1 medications generally or about Wegovy specifically.
The result is a genericized brand name. Like "Kleenex" for tissue or "Band-Aid" for adhesive bandage. The specific brand is not the same as the category, but in casual speech it often gets used that way.
For clinical purposes, precision matters. The drug, the dose, the indication, and the price all change with the specific product, not the category.
FAQ
Is GLP-1 the same as Ozempic? No. GLP-1 is a naturally occurring hormone, and "GLP-1 receptor agonist" is a drug class. Ozempic is one specific medication in that class, brand-name semaglutide for type 2 diabetes.
What is the active ingredient in Ozempic? Semaglutide. Wegovy is also semaglutide, at a different dose and approved indication. Rybelsus is oral semaglutide.
Is Wegovy the same as Ozempic? Both are semaglutide, made by the same company (Novo Nordisk). Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at doses up to 2.4 mg weekly. The active ingredient is the same molecule.
What other GLP-1 drugs are there? Mounjaro and Zepbound (tirzepatide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), Byetta and Bydureon (exenatide), and Rybelsus (oral semaglutide). Each has different doses, indications, and side-effect profiles.
Is Mounjaro a GLP-1? Mounjaro contains tirzepatide, which is a dual GLP-1 and GIP receptor agonist. It activates the GLP-1 receptor along with the GIP receptor, so it is sometimes called a dual incretin agonist rather than a pure GLP-1.
Is tirzepatide stronger than semaglutide? For weight loss, on average yes. SURMOUNT-1 showed 20.9% mean loss at 72 weeks at the 15 mg dose (Jastreboff et al., NEJM 2022) versus 14.9% for semaglutide 2.4 mg in STEP 1 (Wilding et al., NEJM 2021). Individual response varies.
What is the difference between Trulicity and Ozempic? Both are once-weekly GLP-1 receptor agonists for type 2 diabetes. Active ingredients differ (dulaglutide versus semaglutide). Trulicity tends to produce slightly less weight loss and slightly less HbA1c reduction at typical doses.
Is Saxenda a GLP-1? Yes. Saxenda is liraglutide, a daily-injection GLP-1 receptor agonist approved for chronic weight management. Liraglutide is also sold as Victoza for type 2 diabetes.
Are all GLP-1 medications the same dose? No. Doses differ widely. Semaglutide ranges 0.25 to 2.4 mg weekly. Tirzepatide ranges 2.5 to 15 mg weekly. Liraglutide is 0.6 to 3.0 mg daily. The numbers are not directly comparable across drugs because the molecules differ.
Can I switch from Ozempic to Mounjaro? A licensed provider can prescribe a switch if clinically appropriate. The titration starts at the new drug's lowest dose, regardless of where you ended on Ozempic. Cross-tolerance is partial.
Is generic Ozempic available? Not as of 2026. Semaglutide remains under patent protection in the U.S. for several more years. Compounded semaglutide is not the same as a generic.
Is GLP-1 a hormone or a medication? GLP-1 itself is a hormone produced by the gut. The medications people refer to are technically GLP-1 receptor agonists, synthetic molecules that mimic the hormone. The hormone and the medications are related but not the same thing.
Sources
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metab. 2018;27(4):740-756.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373:11-22.
- Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380.
- Novo Nordisk. Ozempic Prescribing Information. Revised 2024.
- Eli Lilly. Mounjaro Prescribing Information. Revised 2024.
- Eli Lilly. Zepbound Prescribing Information. Revised 2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.